PMID- 33204074
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 1177-889X (Print)
IS  - 1177-889X (Electronic)
IS  - 1177-889X (Linking)
VI  - 14
DP  - 2020
TI  - Patient-Reported Outcomes and Impact of Type 2 Diabetes: A Cross-Sectional Study 
      in the Kingdom of Saudi Arabia.
PG  - 2231-2242
LID - 10.2147/PPA.S265126 [doi]
AB  - BACKGROUND: The Kingdom of Saudi Arabia (KSA) has the second highest prevalence 
      of type 2 diabetes mellitus (T2DM) in the Middle East. There is a paucity of 
      research on the experiences and treatment preferences of patients with T2DM in 
      KSA. This study explored Saudi patients' health-related quality of life, eating 
      habits, experiences during Ramadan, and preference between two glucagon-like 
      peptide-1 receptor agonist (GLP-1 RA) treatment devices. METHODS: A 
      cross-sectional, observational study was conducted in three cities in KSA. 
      Participants completed sociodemographic and clinical forms, EQ-5D-5L, Impact of 
      Weight on Self-Perceptions, and a diabetes treatment survey. Participants also 
      viewed instructional videos on GLP-1 RA injection devices and indicated their 
      device preference. RESULTS: Of the 310 participants, 53% were male. The mean age 
      was 43 years (range: 30.0-75.0), duration since diabetes diagnosis was 6.3 years 
      (range: 0.2-27.1), the most commonly reported last HbA1c level was between >/=7.1% 
      and 8% (45%). The mean EQ-5D-5L index score was 0.90, with some participants 
      reporting problems with pain/discomfort (34.5%) and usual activities (33.2%). 
      Patients reported a low-to-moderate impact of weight on self-perception. In 
      preparation for Ramadan, participants sought physician advice on diabetes 
      management (37%) and/or increased checks of their blood glucose (37%). After 
      watching the videos, 89% (n=277) of participants indicated a device preference, 
      with significantly more preferring the dulaglutide device (n=186, 67%) over the 
      semaglutide device (n=91, 33%) (p<0.0001). CONCLUSION: This study indicates that 
      T2DM has a significant social, emotional, and behavioral impact on the lives of 
      patients in KSA.
CI  - (c) 2020 Gelhorn et al.
FAU - Gelhorn, Heather L
AU  - Gelhorn HL
AD  - Evidera, Bethesda, MD, USA.
FAU - Boye, Kristina S
AU  - Boye KS
AD  - Eli Lilly and Company, Indianapolis, IN, USA.
FAU - Shalhoub, Huda
AU  - Shalhoub H
AUID- ORCID: 0000-0003-0230-0149
AD  - Evidera, Bethesda, MD, USA.
FAU - Matza, Louis S
AU  - Matza LS
AD  - Evidera, Bethesda, MD, USA.
FAU - Jordan, Jessica B
AU  - Jordan JB
AD  - Evidera, Bethesda, MD, USA.
FAU - Alhammad, Ali
AU  - Alhammad A
AD  - Eli Lilly and Company, Riyadh, Kingdom of Saudi Arabia.
FAU - Anand, Savita B
AU  - Anand SB
AD  - Evidera, London, UK.
FAU - Ekhzaimy, Aishah A
AU  - Ekhzaimy AA
AUID- ORCID: 0000-0002-8024-0631
AD  - King Saud University, King Saud University Medical City, Riyadh, Kingdom of Saudi 
      Arabia.
FAU - Strizek, Alena
AU  - Strizek A
AUID- ORCID: 0000-0003-4174-4316
AD  - Eli Lilly, Sydney, Australia.
LA  - eng
PT  - Journal Article
DEP - 20201110
PL  - New Zealand
TA  - Patient Prefer Adherence
JT  - Patient preference and adherence
JID - 101475748
PMC - PMC7667182
OTO - NOTNLM
OT  - Kingdom of Saudi Arabia
OT  - health-related quality of life
OT  - impacts
OT  - patient-reported outcomes
OT  - preferences
OT  - type 2 diabetes
COIS- Heather L. Gelhorn, Louis S. Matza, Jessica B. Jordan, Savita B. Anand, and Huda 
      Shalhoub are employees of Evidera, a company that received funding from Eli Lilly 
      for time spent conducting this research. Alena A. Strizek, Kristina S. Boye, and 
      Ali Alhammad are employees of and own stock in Eli Lilly and Company. Dr. Aishah 
      A. Ekhzaimy is not an employee of Eli Lilly and Company and has no conflict of 
      interest to disclose. The authors report no other potential conflicts of interest 
      for this work.
EDAT- 2020/11/19 06:00
MHDA- 2020/11/19 06:01
PMCR- 2020/11/10
CRDT- 2020/11/18 05:57
PHST- 2020/06/26 00:00 [received]
PHST- 2020/10/06 00:00 [accepted]
PHST- 2020/11/18 05:57 [entrez]
PHST- 2020/11/19 06:00 [pubmed]
PHST- 2020/11/19 06:01 [medline]
PHST- 2020/11/10 00:00 [pmc-release]
AID - 265126 [pii]
AID - 10.2147/PPA.S265126 [doi]
PST - epublish
SO  - Patient Prefer Adherence. 2020 Nov 10;14:2231-2242. doi: 10.2147/PPA.S265126. 
      eCollection 2020.